Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advances in allergy management.

P Van Cauwenberge1

  • 1Department of Otorhinolaryngology, University of Ghent, ENT Department, Ghent, Belgium.

Allergy
|December 21, 2002
PubMed
Summary
This summary is machine-generated.

Desloratadine, a selective histamine H1-receptor antagonist, effectively treats multiple allergic conditions including chronic idiopathic urticaria and allergic rhinitis. This non-sedating medication improves quality of life by reducing allergy symptom impact on daily activities and sleep.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Role of nasal sinus infections in the pathogenesis of allergic and inflammatory diseases].

Revue francaise d'allergologie et d'immunologie clinique·2020
Same author

Immunohistochemical studies of wound healing after monopolar electrocautery and ultrasound submucosal inferior nasal turbinate reduction in sheep.

Rhinology·2013
Same author

Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs.

The Journal of allergy and clinical immunology·2012
Same author

Inflammation and remodelling patterns in early stage chronic rhinosinusitis.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2011
Same author

MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine.

Allergy·2011
Same author

Viruses and bacteria in acute asthma exacerbations--a GA² LEN-DARE systematic review.

Allergy·2010
Same journal

Dendritic Cell α-Ketoglutarate Regulates Tfh Polarization in Allergy.

Allergy·2026
Same journal

Decoding the "Metallic" Immune Imprint: Single-Cell Exposomics Reveals the Immune Imprint of Fire Smoke.

Allergy·2026
Same journal

Immunonutrition in Early Life: The Role of Complementary Feeding, Dietary Patterns, and Nutritional Exposures on the Health of Young Children-An EAACI Scoping Review.

Allergy·2026
Same journal

Detergent-Containing Toothpaste Decreases Esophageal Mucosal Impedance and Alters Salivary Properties in Humans.

Allergy·2026
Same journal

Global Variation in Timing of Allergenic Food Introduction for Food Allergy Prevention: An International Survey of Healthcare Professionals.

Allergy·2026
Same journal

Deficiency of Mitochondrial Fatty Acid Enzyme, CPT1A, Underlies Airway Epithelial Barrier Dysfunction in Severe Asthma.

Allergy·2026
See all related articles

Area of Science:

  • Allergy and immunology research.
  • Pharmacology and therapeutic development.

Background:

  • Advances in allergy pathophysiology, epidemiology, and genetics inform the search for novel antiallergy therapies.
  • New therapies aim to intervene in systemic allergic inflammation, offering broad clinical efficacy, improved safety, and enhanced quality of life.

Purpose of the Study:

  • To evaluate desloratadine, a selective histamine H1-receptor antagonist, as a potential new antiallergy therapy.
  • To assess desloratadine's efficacy in managing various allergic conditions and its impact on quality of life.

Main Methods:

  • In vitro studies demonstrating desloratadine's mechanism of action in blocking the allergic inflammatory cascade.
  • Clinical assessment of desloratadine 5 mg once daily in patients with chronic idiopathic urticaria, seasonal allergic rhinitis (SAR), perennial allergic rhinitis, and concomitant asthma.

Related Experiment Videos

Main Results:

  • Desloratadine effectively relieves symptoms of chronic idiopathic urticaria and allergic rhinitis (seasonal and perennial).
  • In patients with asthma and SAR, desloratadine reduced asthma symptoms and beta2-agonist use.
  • Desloratadine demonstrated efficacy against nasal obstruction in SAR, a benefit not seen with many other H1 antagonists.
  • The medication improved quality of life by reducing the impact of allergic symptoms on sleep and daily activities.

Conclusions:

  • Desloratadine is a promising once-daily, non-sedating H1-receptor antagonist with broad efficacy across multiple allergic conditions.
  • Its ability to address nasal obstruction and improve quality of life offers advantages over existing therapies.
  • Desloratadine represents a significant advancement in managing allergic diseases, targeting the systemic inflammatory cascade effectively.